SEC Form 4 · accession 0000899243-19-000568
Dicerna Pharmaceuticals Inc · DRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ralf Rosskamp
Officer — Chief Medical Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $11.77 | Jan 2, 2019 | A | 180,000 | A | — | Jan 2, 2029 | Common Stock | 180,000 | 180,000 | D |
Explanation of responses
- F1The option vests in 48 monthly installments over the four-year period starting on the last day of January 2019, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.